Depo-Provera Lawsuit 2026: Settlement Reached — Who Qualifies Before the November 30 Deadline
The Depo-Provera lawsuit reached a turning point in 2026: Pfizer and plaintiffs' leadership signed a confidential Master Settlement Agreement on July 21, 2026 over meningioma brain-tumor claims, and registration closes on November 30, 2026. If you received Depo-Provera injections and were later diagnosed with a meningioma, this guide explains the evidence, the likely eligibility criteria, and how to file before the deadline.
Key facts
- 6,412 lawsuits were pending in the Depo-Provera MDL as of October 1, 2026, before Judge M. Casey Rodgers in the Northern District of Florida (MDL No. 3140).
- A Master Settlement Agreement was signed on July 21, 2026; the parties estimate roughly 80% of MDL plaintiffs will be eligible.
- Registration closes November 30, 2026; payments are expected to begin in the first quarter of 2027.
- A March 2024 study in The BMJ found that women who used Depo-Provera for more than one year faced a 5.6-fold higher risk of meningioma.
- The FDA-approved label carried no meningioma warning until December 2025.
What Is Depo-Provera and Why Is It Being Sued?
Depo-Provera is an injectable contraceptive made with the synthetic hormone medroxyprogesterone acetate, given as a shot every three months. The lawsuits allege Pfizer failed to adequately warn patients that long-term use could increase the risk of a meningioma. Multidistrict litigation (MDL) is a federal procedure consolidating similar lawsuits before one judge; these cases are centralized as MDL No. 3140 before Judge M. Casey Rodgers in the Northern District of Florida. For how similar MDLs work, see our guides to the Roundup lawsuit and the Suboxone tooth-decay litigation.
The Meningioma Link: What the Research Shows
A meningioma is a tumor growing from the membranes around the brain and spinal cord. Most are non-cancerous, but they can require brain surgery and cause serious lasting symptoms. The claims rest on a March 2024 study in The BMJ finding that women who used Depo-Provera for more than one year had a 5.6 times higher risk of intracranial meningioma. No single study proves causation for an individual patient, but this evidence moved thousands of women to file — and the litigation survived early challenges and grew past 6,400 cases.
The FDA Warning Timeline
A central allegation is timing: the FDA-approved U.S. label carried no meningioma warning until December 2025. Plaintiffs argue women received the injections for years without being told of a risk research was already flagging, while warnings appeared earlier in some other countries. Once the December 2025 label update added the warning, the failure-to-warn argument became substantially harder to dismiss — and the case count kept climbing through 2026.
Where the Litigation Stands in 2026
As of the October 1, 2026 JPML report, 6,412 lawsuits were pending in MDL 3140 and still growing. In June 2026, Pretrial Order No. 30A disclosed a global agreement; on July 21, 2026 the parties signed a Master Settlement Agreement. The first bellwether trial (Toney v. Pfizer) was vacated. In August 2026 the court appointed BrownGreer PLC as settlement administrator and created a common benefit fund for litigation expenses. Claims falling outside the settlement continue toward trial.
The July 2026 Settlement: What We Know
What is public: the agreement is confidential — no aggregate, per-plaintiff, or per-tier payout figure has been disclosed. The parties estimate roughly 80% of federal MDL plaintiffs will qualify. Registration under the procedures approved on July 27, 2026 closes November 30, 2026, and first payments are expected in the first quarter of 2027. Claims outside the criteria are not necessarily dead: lawyers continue reviewing them, and the court's August 2026 orders set discovery for non-participating plaintiffs.
Who Qualifies: The Likely Criteria
The exact eligibility rules are confidential. Based on what handling lawyers report, qualifying claimants generally must show documented Depo-Provera use, a meningioma diagnosis with imaging or pathology records, timing consistent with long-term use (especially over one year), and an unexpired state statute of limitations — some state deadlines run sooner than November 30, 2026. Gather your diagnosis date, injection history, and treatment records now; the mesothelioma guide explains how medical-record proof works in similar injury cases.
The November 30 Deadline and How to File
Settlement registration closes November 30, 2026 — treat this as the date that decides everything. Collect pharmacy and medical records of your injections and diagnosis, then get a free case evaluation: firms handling these claims work on contingency, meaning no upfront cost. Do not wait until the final week — some firms have already stopped accepting new Depo-Provera cases because the deadline is too close to properly investigate a fresh claim.
What Your Claim May Be Worth — Honestly
No public per-case figures exist: the terms are confidential. Your compensation depends on your specific facts — duration of use, tumor severity, whether you needed surgery, lost income, and your state's law. Be skeptical of any calculator promising a precise number; no one outside the settlement process can know your tier.
Who Benefits From This — and Who Does Not
The Depo-Provera settlement covers specific users and has a strict deadline: it helps those who meet the likely criteria a great deal, and others not at all.
Who benefits:
- Long-term users with a meningioma diagnosis — check your records: documented Depo-Provera use, a meningioma diagnosis, and long-term use are the likely criteria, and an estimated 80% of MDL plaintiffs are expected to qualify.
- People who want to act with no upfront cost — firms work on contingency and are paid only if your claim succeeds.
- People approaching the deadline — settlement registration closes November 30, 2026 — start early, because firms need time to investigate.
Who does not benefit:
- People without documented use or a diagnosis — they likely do not meet the criteria, and a lawyer can evaluate their records for free to confirm.
- People who wait until the final week — some state deadlines run sooner, and record review takes time.
Related reading: Camp Lejeune Elective Option 2026: The Payout Grid and Who Qualifies.
Frequently Asked Questions
Is the Depo-Provera lawsuit settled?
A confidential Master Settlement Agreement was signed on July 21, 2026 in MDL 3140. Registration closes November 30, 2026, payments are expected from Q1 2027, and claims outside the criteria may still proceed to trial.
Do I qualify for the Depo-Provera settlement?
The exact criteria are confidential, but qualifying claimants generally show documented Depo-Provera use, a meningioma diagnosis, and long-term use. An estimated 80% of MDL plaintiffs are expected to qualify — a lawyer can evaluate your records for free.
What is the deadline to file?
Settlement registration closes November 30, 2026, and some state deadlines run sooner. Firms need time to investigate, so do not wait until the final week.
Does it cost anything to file?
No upfront cost — firms work on contingency and are paid only if your claim succeeds. For plain-language video explainers on mass-tort topics, see Problem Solved on YouTube.
This article is general educational information about a developing legal matter, not legal advice. Deadlines and procedures change — confirm your deadline with a licensed attorney in your state.
Who benefits most from the Depo-Provera settlement, and how do I start?
Long-term users with a meningioma diagnosis and documented use benefit most — an estimated 80% of MDL plaintiffs are expected to qualify. Start by gathering your medical records and having a firm evaluate them for free, with no upfront cost, before the November 30, 2026 deadline.
Who likely does not qualify?
People without documented Depo-Provera use, without a meningioma diagnosis, or without long-term use likely do not meet the criteria; a lawyer can evaluate your records for free to confirm, and waiting until the final week risks missing sooner state deadlines.